T he perennial promise of human disease genetics is the delivery of etiology-based therapies. This rests on the notion that identifying disease-causing mutations will provide a basis for determining the molecular networks that constitute the disease process-an understanding that is critical for the development of such therapies. On page 506 of this issue, Novarino et al. ( 1) perform what is perhaps the most complete genetic analysis of the neurological disorder hereditary spastic paraplegia (HSP), and deliver on part of this promise by creating an "HSPome," a plausible network of proteins involved in this disease.
In many fi elds, the hard-won discoveries linking mutations to diseases are the foundation for investigations into molecular pathogenesis. In rare instances, mutation detection has provided immediate insight into the disease process. Usually, however, moving from gene to pathogenesis has been exceptionally diffi cult. Functional and mechanistic work on the molecular etiology of disease remains one of the major challenges in modern biology; this is quite understandable given the inherent limitations of traditional reductionist functional work. There have been successes, however, and these have helped form the dominant theories of pathogenesis for many diseases, including Alzheimer's disease ( 2) . An increasingly popular intermediate step between genetics and function is the use of pathways-based analysis. Such an approach attempts not only to produce a refi ned list of potential functional interactions to investigate at the bench, but also to provide a global snapshot of the landscape of a particular disease's etiology.
Novarino et al. have executed this approach with compelling results. The underlying strategy of their study involved the identifi cation of disease-causing mutations using the power of small, inbred families. HSPs represent a class of inherited progressive neurodegenerative disorders that manifest with stiffness and contraction in the lower limbs-a feature believed to be the result of corticospinal tract dysfunction. These diseases are extremely genetically heterogeneous. Novarino et al. examined the autosomal recessive form (AR-HSP), which was already linked to mutation of more than 20 genes ( 3) . The authors expand this list by means of an iterative set of analyses on an initial set of 55 AR-HSP families. Using a straightforward genetic strategy of segregation, they show that disease in one-third of the families is linked to genes previously implicated in AR-HSP, but they also identify new candidate gene mutations in more than half of the remaining families. Additional mutations were identifi ed in one-third of these new genes, providing substantive genetic support for causality. Functional analysis showed that candidate gene mutations cause a locomotor defi cit in an animal model (zebrafi sh) of HSP, consistent with what has been described in previous HSP modeling efforts, thus further supporting pathogenicity.
Beyond identifying new genes associated with HSP, Novarino et al. constructed a proLaboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA. E-mail: singleta@mail.nih.gov ments confi rmed that MRP2 is an active protease and can be effectively inhibited only by PmEPIC1. Thus, EPIC1 effectors function more effectively on their respective hosts, supporting the hypothesis of effector specialization after a host jump.
To defi ne the biochemical basis of EPIC1 host specialization, Dong et al. inferred the ancestral allele of epiC1 using maximum likelihood methods. Ancestral EPIC1 had similar specifi city as P. infestans EPIC1 for RCR3. Thus, the ability of PmEPIC1 to function more effectively on MRP2 was likely acquired after host jumping.
Surprisingly, both EPIC1 and PmEPIC1 can bind MRP2 using co-immunoprecipitation. Competition experiments show that binding likely occurs at the active site of MRP2 for both EPIC1 and PmEPIC1. How can two similar EPIC1 effectors exhibit different target specifi city while still binding to both effective and ineffective targets? Analyses of variant amino acid residues superimposed on an existing structure of tarocystatin in complex with papain protease ( 6) indicate that EPIC1 effectors have similar folds and likely bind proteases at three sites, two of which are polymorphic. A single amino acid polymorphism in PmEPIC1 and its corresponding protease, MRP2, determine specifi city.
Future experiments are needed to determine whether PmEPIC1 provides a fi tness advantage. If it does, then this would validate the importance of effector specialization for disease biology. These experiments are possible but likely to be diffi cult to interpret. Oomycete genomes contain large effector arsenals, with ~563 cell-entering effectors in P. infestans ( 7) 
By exploring both evolutionary pressures and biochemical adaptation of EPIC1 and corresponding host proteases, Dong et al. reveal that selection for single amino acid polymorphisms can signifi cantly affect effector specialization. These findings open an exciting new door to understanding the role effectors play in shaping pathogen adaptation. Conserved core effectors undergoing positive selection could be promising targets for disease control. Nature's ability to select for biochemical specialization has implications for engineering enzymes and their corresponding targets for enhanced specifi city. Undoubtedly, many important secrets remain to be discovered.
I
n Arabidopsis, a small group of undifferentiated stem cells in the center of the fl oral meristem give rise to the fl ower. These stem cells produce daughter cells that differentiate into the four whorls of organs (sepals, petals, stamens, and carpels) underlying the basic fl ower structure. The different organ identities are determined by the complex interplay of fl oral organ identity genes, most of which are transcription factors. On page 505 in this issue, Sun et al. ( 1) describe an elegant timing mechanism that allows transcriptional changes specifi ed in the stem cells to be executed only in daughter cells and only after a predefi ned number of cell divisions.
The meristem identity gene WUSCHEL (WUS) is required to maintain the stem cell population in the fl oral meristem. The transcription factor AGAMOUS (AG) drives differentiation of the stem cells into stamens and carpels and is induced by both the fl oral activator LEAFY (LFY) and WUS in early fl owers (stage 3). At a later stage (stage 6), AG represses WUS in a negative feedback loop to convert the stem cells to organ primordia ( 2) (see the fi gure). Although AG induction by WUS, and WUS repression by AG, both
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Department of Plant Biology, University of Georgia, Athens, GA 30602, USA. E-mail: xiaoyu@plantbio.uga.edu teome network for HSP from information available in protein interaction databases. They observed that candidate genes and known HSP genes were more highly connected within this network than expected by chance. The authors then created a network of proteins encoded by known HSP genes, their nominated candidate genes, and proximal interactors, naming this expanded network the "HSPome."
This not only provides a global view of the processes and proteins underlying HSP, but also identifi es genes as new candidates to bear disease-causing mutations. Novarino et al. validated this last point by returning to genetics. They identifi ed likely pathogenic variants in three new genes mined from the HSPome, one of which was independently implicated in HSP ( 4).
Novarino et al. illustrate a subtle and perhaps necessary shift in genetics work. The burden of proving mutation pathogenicity has traditionally rested on the shoulders of genetics alone, relying on association of mutations with disease, segregation of mutations within families, and independent replication of results. Given the pace and nature of genetic mutation discovery, these proofs are no longer always tenable. Instead, genetics increasingly relies on functional and bioinformatics work. This change has been contentious among those who believe that genetic evidence should be the foundation of functional work. There is admittedly potential danger in using functional work to identify candidate genes-most important is the inevitable issue of circularity where studies are limited to what investigators believe to be biologically plausible genes and proteins. This runs the risk not only of incorrectly self-affi rming hypotheses, but also of ignoring new and critically important pathways because they don't fi t into a current understanding of the disease process. This is not the case in the study by Novarino et al. The authors have been careful to question the signifi cance of their observations, and they have in some instances the reassurance of independent replication. It is exactly this type of care that the fi eld needs to take.
Novarino et al. also examined the relationship of the HSPome to genes implicated in other diseases, and found signifi cant overlap with gene sets linked to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. If this fascinating observation holds true, it raises a critical question: If varied neurodegenerative disorders are linked by a common pathway, what is the underlying cause of the distinct cellular vulnerability seen in these disorders? One might predict that identifying disease-linked protein networks is a key step toward understanding this phenomenon. In this regard, the type of work described by Novarino et al. shows not only the power of comprehensive genetic analysis in identifying the pathogenic networks involved in that disease but also the potential of such work to inform outside of the disease in question (see the fi gure).
This study clearly adds another dimension to our understanding of HSP. With this knowledge, we can turn toward fulfi lling the ultimate promise of genetics: translating this understanding into etiology-based therapies.
